Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMG 562
- Development stage
- Discontinued
- Lead developer
- Amgen
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AMG 562 is a bispecific T-cell engager (BiTE) antibody construct developed by Amgen for the treatment of B-cell malignancies. It targets both CD19, a protein expressed on malignant B cells, and CD3, found on cytotoxic T lymphocytes. By binding to these antigens, AMG 562 redirects and activates cytotoxic T cells to recognize and kill CD19-expressing tumor cells through CTL-mediated lysis. The drug was investigated in phase 1 clinical trials for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). However, development has been discontinued[1][2][4][5][8].
- Other names
- anti-cd19/cd3 bite antibody amg 562
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on AMG 562.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMG 562.